Sheue-yann Cheng
Senior Investigator
Center for Cancer Research
National Cancer Institute
United States of America
Biography
Dr. Sheue-yann Cheng obtained her Ph.D. from the University of California, San Francisco Medical Center. She received her postdoctoral training at the University of Chicago and the National Institute of Diabetes and Digestive and Kidney Diseases. She joined the NCI as a senior investigator in 1979 and was promoted to Section Chief in 1991. Dr. Cheng is a recipient of the NIH Merit Award for outstanding achievements, the Scientific Achievement Award from the Chinese Medical and Health Association, the Charles Harkin Award of the NCI, the Sidney H. Ingbar Distinguished Lectureship Award of the American Thyroid Association, and the Abbott Thyroid Research Clinical Fellowship Mentor Award of The Endocrine Society. She served as a regular member of the NIH Molecular and Cellular Endocrinology Study Session and as an advisor for Howard Hughes Medical Institute-NIH Research Scholars. Currently she is a Women Scientist Advisor of the Center of Cancer Research, NCI and is on the Editorial Boards of several prominent journals. Dr. Cheng research focuses on understanding the biology and molecular actions of thyroid hormone receptors in health and disease. Dr. Cheng describes her current research below.
Research Interest
gene regulation, mutant receptors, thyroid disease, metastatic thyroid cancer, molecular targeting, mouse models
Publications
-
Kim WG, Guigon CJ, Fozzatti L, Park JW, Lu C, Willingham MC, Cheng SY. SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer. Clinical Cancer Research. 2012 Mar 1;18(5):1281-90.
-
Fozzatti L, Lu C, Kim DW, Park JW, Astapova I, Gavrilova O, Willingham MC, Hollenberg AN, Cheng SY. Resistance to thyroid hormone is modulated in vivo by the nuclear receptor corepressor (NCOR1). Proceedings of the National Academy of Sciences. 2011 Oct 18;108(42):17462-7.
-
Furuya F, Hanover JA, Cheng SY. Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone β receptor. Proceedings of the National Academy of Sciences of the United States of America. 2006 Feb 7;103(6):1780-5.
